We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Silica Microparticles Effectively Transport Anticancer Antibodies

By LabMedica International staff writers
Posted on 01 Jun 2010
Microparticles of porous silica (functionalized mesoporous silica, or FMS) have been used to transport effectively anticancer antibodies that slowed the growth of melanoma tumors in a mouse model.

Investigators at the University of Washington (Seattle, USA) loaded chemically modified silica microparticles to a very high density with antibodies specific to the CTLA4 cell surface protein, which is present on many types of cancer cells including melanoma. More...
The particles were approximately 6 µm to 12 µm in diameter and contained pores of about 30 nm in diameter. The pores were loaded to a super high density of about 0.4 mg − 0.8 mg of antibody per mg of FMS. Chemical modification of the FMS particles guaranteed long-lasting local release of the antibodies at the site of injection.

Results published in the May 3, 2010, online edition of the Journal of the American Chemical Society (JACS) revealed that FMS-anti-CTLA4 antibody injected directly into a mouse melanoma induced much greater and extended inhibition of tumor growth than did the antibody when given systemically or after having been injected into the tumor without microparticle carriers. Microparticle treatment prolonged the lives mice with melanoma. Of five mice that had been treated with particles alone (no antibody), all died within 21 days after treatment. In contrast, of the five mice treated with FMS-antibodies, three survived 21 days, and two were still alive at 34 days, when the experiment ended.

"We want to understand the mechanism, because not much is known about how the slowly leaked antibodies induce changes in the immune system or in the microenvironment of the tumor," said senior author Dr. Karl Erik Hellstrom, professor of pathology at the University of Washington.

Related Links:
University of Washington



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.